ADVANCES IN RESPIRATORY INNOVATION AND TECHNOLOGY SYMPOSIUM A HUGE SUCCESS

 

The most important biennial meeting in China for sharing inhalation science and technology innovation

This two-day scientific symposium hosted by the SFDA training center welcomed an audience of more than 150 participants from China, Europe and the USA.

A panel of 23 highly renowned speakers debated current domestic Chinese and foreign HFA aerosol regulations. Other topics addressed the market outlook, and future development trends of aerosols including Dry Powder Inhalers and nasal sprays:

•    Dr Ping Wang, SFDA National Pharmacopeia committee: “An overview of SFDA quality requirements for inhaled
     drugs”
•    Dr Qiming Zhang, National Institute for Food and Drug Control: “Control of related substance profiles in inhaled
     drugs”
•    Dr Huimin Sun, National Institutes for Food and Drug Control: “The quality requirements of HFA from SFDA”
•    Dr Guiliang Chen, Shanghai Institute for Food and Drug Control: “CFC to HFA transition: what are the key quality
     attributes of HFA MDIs?”
•    Dr Dave Parkins, GSK: “Challenges in demonstrating in vitro bioequivalence between different DPIs”
•    Dr Tushar Shah, Teva: “Challenges in demonstrating in vivo bioequivalence between OIPs”
•    Dr Xian-Ming Zeng, Teva: “Quality by Design (QbD) and Process Analytical Technology (PAT) in development
     and commercial manufacture of inhaled drugs”
•    Dr Gerallt Williams, Aptar Pharma: “Evolution of MDI formulations and device components”
•    Dr Hak-Kim Chan, University of Sydney: “Inhalation aerosol drug delivery: current research and global trends”
•    Dr Guillaume Brouet, Aptar Pharma: “DPI device situation introduction”

 
Aptar Pharma’s market leadership in China

Established since 1996 in Suzhou, near Shanghai, Aptar Pharma has more than 265 employees operating in a 4,500 m² state-of-the-art factory. We provide innovative
and proven aerosol, spray and dispensing systems, to biotechnology, healthcare and pharmaceutical companies in China.

Aptar Pharma was ahead of the game in gaining expertise in HFA aerosols from the early 1990s, and in particular about how these formulations interact with metering valve components within a pressurized Metered Dose Inhaler.

The combination of in-house development and manufacturing of elastomer gaskets with the deployment of a dedicated HFA valve development team has allowed Aptar Pharma to become world leader in this segment.

Aptar Pharma is a recognized market leader in Asia, including China, and continues to expand its activity, leveraging an in-depth network of local partners to forge strong links with a wide range of local players, including those in research, industry, academia and regulatory bodies.

“As market leader in China, Aptar Pharma was very pleased to have contributed to this highly successful event with our host, the SFDA training center”, said Marc Prieur, President Aptar Pharma Asia. “A great amount of interest and high level scientific exchange has been shown in this symposium, both from China and international participants.”

About Aptar Pharma

Aptar Pharma is part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by years of proven expertise.

Aptargroup (NYSE: ATR) is headquartered in the US and has manufacturing sites in North America, Europe, Asia and South America. For more information, visit www.aptar.com.

Press Contacts

Elisa Eschylle, Events and Press relations manager
Tel.: + 33 (0)1 39 17 20 41
Email : elisa.eschylle@aptar.com

Marion Baschet Vernet
Tel.: +44 (0)797 609 4100
Email : mbvernet@gmail.com

Download the press release in PDF format

< Back